CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
CNS Pharmaceutical has raised $22.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in May 2026.
CNS Pharmaceutical's investors include Nazare Partners, ADAR1 Capital Management, Stonepine Capital Management, Ikarian Capital.
CNS Pharmaceutical is headquartered in Houston, United States.
CNS Pharmaceutical is a pre-clinical stage biotechnology company specializing in the development of novel treatments for brain tumors.
CNS Pharmaceutical is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CNS Pharmaceutical — Funding & Investors." VCBacked, May 4, 2026, https://www.vcbacked.co/company/cns-pharmaceutical. Accessed September 30, 2026.
VCBacked. (2026). CNS Pharmaceutical — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/cns-pharmaceutical
{{cite web |title=CNS Pharmaceutical — Funding & Investors |url=https://www.vcbacked.co/company/cns-pharmaceutical |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated